Thermo Fisher
TMO · NYSE · Healthcare · Life-Science Tools, CDMO & Clinical Research
LIVE MARKET DATA NOT YET CONNECTED — price, movement, and market cap will appear here with source and timestamp once a data provider is integrated.
Red Cardinal Snapshot
WHAT IT DOES
Thermo Fisher sells laboratories almost everything they use. The instruments that let scientists see molecules — mass spectrometers that weigh them, electron microscopes that image them. The consumables they burn through daily: pipette tips, plastics, reagents, chemicals, the vast Fisher Scientific catalog. The equipment that grows biologic drugs in stainless-steel and single-use bioreactors. And two service businesses that go further: Patheon, which manufactures finished drugs on behalf of pharmaceutical companies, and PPD, which runs their clinical trials.
HOW IT MAKES MONEY
Two economies stacked on each other. Instruments are big-ticket capital purchases — lumpy, tied to customer budgets, sold once and serviced for a decade. Consumables and services are the recurring base: labs reorder every week, drug-manufacturing contracts run for years, trials run for years. Roughly speaking, the razors are the instruments and the blades are everything else, and the blades are the larger and steadier half.
WHY WE TRACK IT
Thermo Fisher is the closest thing public markets have to an index fund on life-science activity. Its organic growth is, in aggregate, the sector's R&D spending — academic, biotech, pharma, government, industrial. That makes it the single best read on whether the science economy is expanding or contracting, and it makes the current policy moment unusually legible: NIH funding cuts, pharma pipeline triage under drug-pricing pressure, China weakness, and biotech's funding winter all land on the same customer base at once.
THE SIMPLE THESIS
Own the infrastructure, not the outcome. Thermo Fisher doesn't need to guess which drug wins, because it sells to everyone trying — an aggregation strategy assembled through decades of acquisitions. The open question is whether that diversification genuinely smooths a research-funding downturn, or merely averages the pain across segments that are all feeling the same squeeze.
PREMIUM RESEARCH
The rest of the Thermo Fisher dossier
The Five Minute Brief, our intelligence rating and thesis health, the competitive position, the bull and bear cases, what would invalidate the thesis, and every source behind it.
- Five Minute Brief
- Intelligence rating and thesis health
- Competitive position and moat analysis
- Bull case, bear case, and what breaks it
- Systemic importance and cascade effects
- Full source list and methodology
Subscribe to the newsletter and choose 3 dossiers to read in full — this one included, if you like.
Free, and you pick the companies. No card required.